{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:22:13Z","timestamp":1790194933183,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100018696","name":"R\u00e9gion Normandie","doi-asserted-by":"publisher","award":["R\u00e9gion Normandie"],"award-info":[{"award-number":["R\u00e9gion Normandie"]}],"id":[{"id":"10.13039\/501100018696","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00259-026-07823-4","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T01:44:20Z","timestamp":1772847860000},"page":"4883-4894","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical value of per-treatment whole-body single-time-point automated dosimetry for [177Lu]Lu-PSMA-617 therapy in metastatic castration-resistant prostate cancer"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2825-2085","authenticated-orcid":false,"given":"Arnaud","family":"Dieudonn\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Terro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Dumouchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol\u00e8ne","family":"Perret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Pommier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Edet-Sanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Di Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Augusto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Decazes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tonnelet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"key":"7823_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, Pekala KR, Matsoukas K, et al. 2022 Update on Prostate Cancer Epidemiology and Risk Factors\u2014A Systematic Review. Eur Urol. 2023;84:191\u2013206.","journal-title":"Eur Urol"},{"key":"7823_CR2","first-page":"339","volume":"14","author":"F Turco","year":"2022","unstructured":"Turco F, Gillessen S, Cathomas R, Buttigliero C, Vogl UM. Treatment landscape for patients with castration-resistant prostate cancer: patient selection and unmet clinical needs. Res Rep Urol. 2022;14:339\u201350.","journal-title":"Res Rep Urol"},{"key":"7823_CR3","doi-asserted-by":"crossref","unstructured":"Kratochwil C, Fendler WP, Eiber M et al. May. Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023.","DOI":"10.1007\/s00259-023-06255-8"},{"key":"7823_CR4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"key":"7823_CR5","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","volume":"44","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Eiber M, Beheshti M, et al. 68Ga-PSMA PET\/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014\u201324.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7823_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-019-0548-z","volume":"9","author":"A Gosewisch","year":"2019","unstructured":"Gosewisch A, Ilhan H, Tattenberg S, et al. 3d monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3d localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT\/CT. EJNMMI Res. 2019;9:76.","journal-title":"EJNMMI Res"},{"key":"7823_CR7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"J Violet","year":"2019","unstructured":"Violet J, Jackson P, Ferdinandus J, et al. Dosimetry of 177 Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes. J Nucl Med. 2019;60:517\u201323.","journal-title":"J Nucl Med"},{"key":"7823_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-020-00311-0","volume":"7","author":"A Rinscheid","year":"2020","unstructured":"Rinscheid A, Kletting P, Eiber M, Beer AJ, Glatting G. Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry. EJNMMI Phys. 2020;7:41.","journal-title":"EJNMMI Phys"},{"key":"7823_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2967\/jnumed.117.193706","volume":"59","author":"H H\u00e4nscheid","year":"2018","unstructured":"H\u00e4nscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Dose mapping after endoradiotherapy with 177Lu-DOTATATE\/DOTATOC by a single measurement after 4 days. J Nucl Med. 2018;59:75\u201381.","journal-title":"J Nucl Med"},{"key":"7823_CR10","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.2967\/jnumed.119.233411","volume":"61","author":"PA Jackson","year":"2020","unstructured":"Jackson PA, Hofman MS, Hicks RJ, Scalzo M, Violet J. Radiation dosimetry in 177Lu-PSMA-617 therapy using a single posttreatment SPECT\/CT scan: a novel methodology to generate time- and tissue-specific dose factors. J Nucl Med. 2020;61:1030\u20136.","journal-title":"J Nucl Med"},{"key":"7823_CR11","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2967\/jnumed.122.264594","volume":"64","author":"J Brosch-Lenz","year":"2023","unstructured":"Brosch-Lenz J, Delker A, V\u00f6lter F, et al. Toward single-time-point image-based dosimetry of 177Lu-PSMA-617 therapy. J Nucl Med. 2023;64:767\u201374.","journal-title":"J Nucl Med"},{"key":"7823_CR12","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s00259-024-07010-3","volume":"52","author":"J Hu","year":"2025","unstructured":"Hu J, Seifert R, Karkampouna S, et al. Influence of dosimetry accuracy on the correlation with treatment outcome in a preliminary PSMA radiopharmaceutical therapy study. Eur J Nucl Med Mol Imaging. 2025;52:1649\u201357.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7823_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41592-020-01008-z","volume":"18","author":"F Isensee","year":"2021","unstructured":"Isensee F, Jaeger PF, Kohl SAA, Petersen J, Maier-Hein KH. nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation. Nat Methods. 2021;18:203\u201311.","journal-title":"Nat Methods"},{"key":"7823_CR14","doi-asserted-by":"crossref","unstructured":"Wasserthal J, Meyer M, Breit H-C, Cyriac J, Yang S, Segeroth M. TotalSegmentator: robust segmentation of 104 anatomical structures in CT images. 2022.","DOI":"10.1148\/ryai.230024"},{"key":"7823_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40658-025-00727-6","volume":"12","author":"A Dieudonn\u00e9","year":"2025","unstructured":"Dieudonn\u00e9 A, Terro A, Dumouchel A, et al. Towards fully automatized [177Lu]Lu-PSMA personalized dosimetry based on 360\u00b0 CZT whole-body SPECT\/CT: a proof-of-concept. EJNMMI Phys. 2025;12:25.","journal-title":"EJNMMI Phys"},{"key":"7823_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/mp.18076","volume":"52","author":"A Terro","year":"2025","unstructured":"Terro A, Perret S, Dumouchel A, et al. Validation of the collapsed-cone superposition for whole-body patient-specific dosimetry in [177Lu]Lu-PSMA-617 radionuclide therapy. Med Phys. 2025;52:e18076.","journal-title":"Med Phys"},{"key":"7823_CR17","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1002\/mp.12886","volume":"45","author":"MT Madsen","year":"2018","unstructured":"Madsen MT, Menda Y, O\u2019Dorisio TM, O\u2019Dorisio MS. Technical note: single time point dose estimate for exponential clearance. Med Phys. 2018;45:2318\u201324.","journal-title":"Med Phys"},{"key":"7823_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-018-0386-4","volume":"8","author":"J Kurth","year":"2018","unstructured":"Kurth J, Krause BJ, Schwarzenb\u00f6ck SM, Stegger L, Sch\u00e4fers M, Rahbar K. External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies. EJNMMI Res. 2018;8:32.","journal-title":"EJNMMI Res"},{"key":"7823_CR19","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.2967\/jnumed.120.242057","volume":"61","author":"R Seifert","year":"2020","unstructured":"Seifert R, Herrmann K, Kleesiek J, et al. Semiautomatically Quantified Tumor Volume Using 68Ga-PSMA-11 PET as a Biomarker for Survival in Patients with Advanced Prostate Cancer. J Nucl Med. 2020;61:1786\u201392.","journal-title":"J Nucl Med"},{"key":"7823_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2967\/jnumed.123.265448","volume":"65","author":"K Herrmann","year":"2024","unstructured":"Herrmann K, Rahbar K, Eiber M, et al. Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy. J Nucl Med. 2024;65:71\u20138.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07823-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07823-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07823-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T09:24:24Z","timestamp":1780997064000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07823-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["7823"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07823-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The Institutional Review Board approved the study (2405B).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Arnaud Dieudonn\u00e9 received research support by Guerbet France; received payment for lectures from Sirtex Medical France; received payment for board membership from Boston Scientific SAS and Novartis Pharma SAS. All other authors declare no conflicts of interest regarding financial or non-financial relationships that could influence the objectivity of this research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}